These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25439374)

  • 1. Clinical and immunologic assessment of a cluster method during allergen immunotherapy refill dosing.
    Waibel KH; Owens TJ; Crisp HC; Gomez RA
    J Allergy Clin Immunol Pract; 2014; 2(6):793-4. PubMed ID: 25439374
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of allergen injection immunotherapy in real life.
    Borghesan F; Manzotti G
    Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):63-4. PubMed ID: 23821836
    [No Abstract]   [Full Text] [Related]  

  • 3. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sublingual vs subcutaneous immunotherapy].
    Olivé Pérez A
    Rev Alerg Mex; 2004; 51(1):29-35. PubMed ID: 15119753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy.
    Cochard MM; Eigenmann PA
    J Allergy Clin Immunol; 2009 Aug; 124(2):378-9. PubMed ID: 19541352
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile.
    Calderón MA; Simons FE; Malling HJ; Lockey RF; Moingeon P; Demoly P
    Allergy; 2012 Mar; 67(3):302-11. PubMed ID: 22150126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local reactions from subcutaneous allergen immunotherapy.
    Coop CA
    Immunotherapy; 2013 Dec; 5(12):1339-45. PubMed ID: 24283844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shooting for a faster approach to the immunotherapy target: will cluster become conventional?
    Cox LS
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062
    [No Abstract]   [Full Text] [Related]  

  • 11. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of an unusual cluster of systemic reactions to subcutaneous specific immunotherapy with respiratory allergens in one allergy center.
    Scherer K; Schindler C; Arnold A; Bach S; Bircher AJ
    Int Arch Allergy Immunol; 2012; 157(3):318-20. PubMed ID: 22056648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unusual, delayed, localized bullous reaction after subcutaneous allergen immunotherapy.
    Gonzalez-Estrada A; Glancy E; Nolder P; Paschall V
    J Allergy Clin Immunol Pract; 2014; 2(6):791-2. PubMed ID: 25439373
    [No Abstract]   [Full Text] [Related]  

  • 14. Do indications to sublingual immunotherapy need to be revised?
    Incorvaia C; Mauro M
    J Allergy Clin Immunol; 2010 Jan; 125(1):277; author reply 277-8. PubMed ID: 20109757
    [No Abstract]   [Full Text] [Related]  

  • 15. Observational study of the safety of a cluster schedule for subcutaneous immunotherapy in a pediatric population.
    Peñas A; García-González M; Cruz MJ; Valdesoiro L; Boot JD; Larramona H; Asensio O; Grau R; Costa J; Bosque M
    J Investig Allergol Clin Immunol; 2013; 23(1):63-5. PubMed ID: 23653981
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal dosing of allergen immunotherapy: efficacy, safety, long-lasting effect.
    Senna G; Crivellaro MA; Bonadonna P; Dama AR; Schiappoli M; Passalaqua
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):386-92. PubMed ID: 14768524
    [No Abstract]   [Full Text] [Related]  

  • 17. The optimal immunotherapy cluster schedule in clinical practice.
    Fernández-Távora L; Moreno C; Martín S; Rico P
    J Investig Allergol Clin Immunol; 2003; 13(3):193-201. PubMed ID: 14635470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy.
    Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F
    J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007
    [No Abstract]   [Full Text] [Related]  

  • 19. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients.
    Rogala B; Markiewicz-Bendkowska IB; Brzoza Z; Glück J; Oleś E
    Rhinology; 2007 Jun; 45(2):134-9. PubMed ID: 17708460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
    Howarth P; Malling HJ; Molimard M; Devillier P
    Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.